Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MECP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MECP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MECP2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MECP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007048219 | Oral cavity | OSCC | response to oxygen levels | 200/7305 | 347/18723 | 1.17e-12 | 5.13e-11 | 200 |
GO:00435434 | Oral cavity | OSCC | protein acylation | 149/7305 | 243/18723 | 1.33e-12 | 5.80e-11 | 149 |
GO:00070526 | Oral cavity | OSCC | mitotic spindle organization | 85/7305 | 120/18723 | 1.44e-12 | 6.23e-11 | 85 |
GO:19028506 | Oral cavity | OSCC | microtubule cytoskeleton organization involved in mitosis | 99/7305 | 147/18723 | 2.94e-12 | 1.18e-10 | 99 |
GO:190290520 | Oral cavity | OSCC | positive regulation of supramolecular fiber organization | 131/7305 | 209/18723 | 3.18e-12 | 1.27e-10 | 131 |
GO:005105414 | Oral cavity | OSCC | positive regulation of DNA metabolic process | 126/7305 | 201/18723 | 8.12e-12 | 3.01e-10 | 126 |
GO:00070517 | Oral cavity | OSCC | spindle organization | 117/7305 | 184/18723 | 1.16e-11 | 4.17e-10 | 117 |
GO:000166619 | Oral cavity | OSCC | response to hypoxia | 177/7305 | 307/18723 | 2.21e-11 | 7.50e-10 | 177 |
GO:19019905 | Oral cavity | OSCC | regulation of mitotic cell cycle phase transition | 173/7305 | 299/18723 | 2.49e-11 | 8.35e-10 | 173 |
GO:007099720 | Oral cavity | OSCC | neuron death | 202/7305 | 361/18723 | 3.75e-11 | 1.23e-09 | 202 |
GO:00183944 | Oral cavity | OSCC | peptidyl-lysine acetylation | 108/7305 | 169/18723 | 4.55e-11 | 1.45e-09 | 108 |
GO:00064734 | Oral cavity | OSCC | protein acetylation | 124/7305 | 201/18723 | 5.59e-11 | 1.74e-09 | 124 |
GO:190290320 | Oral cavity | OSCC | regulation of supramolecular fiber organization | 211/7305 | 383/18723 | 9.45e-11 | 2.88e-09 | 211 |
GO:003629319 | Oral cavity | OSCC | response to decreased oxygen levels | 182/7305 | 322/18723 | 1.14e-10 | 3.41e-09 | 182 |
GO:005149518 | Oral cavity | OSCC | positive regulation of cytoskeleton organization | 135/7305 | 226/18723 | 1.98e-10 | 5.66e-09 | 135 |
GO:005125820 | Oral cavity | OSCC | protein polymerization | 169/7305 | 297/18723 | 2.57e-10 | 7.17e-09 | 169 |
GO:000931416 | Oral cavity | OSCC | response to radiation | 241/7305 | 456/18723 | 9.76e-10 | 2.40e-08 | 241 |
GO:00165734 | Oral cavity | OSCC | histone acetylation | 96/7305 | 152/18723 | 1.35e-09 | 3.29e-08 | 96 |
GO:00183934 | Oral cavity | OSCC | internal peptidyl-lysine acetylation | 99/7305 | 158/18723 | 1.41e-09 | 3.39e-08 | 99 |
GO:00064754 | Oral cavity | OSCC | internal protein amino acid acetylation | 100/7305 | 160/18723 | 1.43e-09 | 3.41e-08 | 100 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MECP2 | SNV | Missense_Mutation | rs587783137 | c.604C>T | p.Arg202Cys | p.R202C | P51608 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A0CO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
MECP2 | SNV | Missense_Mutation | rs61748389 | c.434N>A | p.Arg145His | p.R145H | P51608 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MECP2 | SNV | Missense_Mutation | | c.930N>C | p.Glu310Asp | p.E310D | P51608 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-AO-A03L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
MECP2 | SNV | Missense_Mutation | | c.1363N>C | p.Ala455Pro | p.A455P | P51608 | protein_coding | deleterious_low_confidence(0.05) | benign(0.001) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
MECP2 | SNV | Missense_Mutation | | c.289N>T | p.Arg97Cys | p.R97C | P51608 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MECP2 | SNV | Missense_Mutation | rs61753966 | c.1270G>A | p.Val424Ile | p.V424I | P51608 | protein_coding | tolerated(0.41) | benign(0) | TCGA-B6-A1KI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MECP2 | SNV | Missense_Mutation | rs61751444 | c.961C>T | p.Arg321Trp | p.R321W | P51608 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MECP2 | insertion | Nonsense_Mutation | novel | c.888_889insGCAAACCAACAAGAATAAAGGCAGCTGTTGTCTCTT | p.Lys296_Lys297insAlaAsnGlnGlnGluTerArgGlnLeuLeuSerLeu | p.K296_K297insANQQE*RQLLSL | P51608 | protein_coding | | | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
MECP2 | insertion | In_Frame_Ins | novel | c.1376_1377insCACCGCCGCCACGGCCGC | p.Thr454_Ala459dup | p.T454_A459dup | P51608 | protein_coding | | | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
MECP2 | deletion | Frame_Shift_Del | novel | c.933delC | p.Val312TyrfsTer21 | p.V312Yfs*21 | P51608 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |